Navitoclax (ABT-263) Rejuvenates Human Skin by Eliminating Senescent Dermal Fibroblasts in a Mouse/Human Chimeric...

Area of Science:

• Gerontology and Dermatology
• Cellular Biology and Aging Research

Background:

• Chronic senescence, including aging, drives age-related tissue dysfunction and disease.
• Senescent fibroblasts and their secretory phenotype are key contributors to this process.
• Removing senescent cells shows potential for preventing tissue dysfunction and extending lifespan.

Purpose of the Study:

• To investigate the rejuvenating effects of ABT-263 (navitoclax) on aging human skin.
• To determine if ABT-263 can selectively eliminate senescent skin cells.
• To assess the impact of ABT-263 on the aging skin phenotype in a human skin graft mouse model.

Main Methods:

• Induction of senescence in human skin fibroblasts and assessment of ABT-263 viability.
• Transplantation of aged human skin onto nude mice.
• Intraperitoneal injection of ABT-263 or control to the mouse model.
• Analysis of skin specimens for senescent cell count, secretory phenotype markers, and collagen density.

Main Results:

• ABT-263 treatment led to the selective elimination of senescent dermal fibroblasts in aged human skin grafts.
• A significant decrease in senescent cell numbers and aging-related secretory phenotype molecules (MMPs, interleukins) was observed.
• Treatment resulted in an increase in collagen density within the treated skin specimens.
• No adverse side effects were noted in the ABT-263 treated group.

Conclusions:

• Selective removal of senescent skin cells using ABT-263 can effectively improve the aging phenotype of human skin.
• ABT-263 demonstrates potential as a novel therapeutic agent for combating skin aging.
• The findings support ABT-263's role in mitigating age-related skin deterioration.